Acer Therapeutics Inc
F:P6NA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Paragon Globe Bhd
KLSE:PARAGON
|
MY |
|
Automotive Finco Corp
XTSX:AFCC.H
|
CA |
Acer Therapeutics Inc
Research & Development
Acer Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acer Therapeutics Inc
F:P6NA
|
Research & Development
-$11.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-7%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Acer Therapeutics Inc
Glance View
Acer Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Newton, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2006-09-01. The Company’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate), ACER-801 (osanetant), EDSIVO (celiprolol) and ACER-2820 (emetine). ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for the treatment of induced vasomotor symptoms (iVMS); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19.
See Also
What is Acer Therapeutics Inc's Research & Development?
Research & Development
-11.9m
USD
Based on the financial report for Dec 31, 2022, Acer Therapeutics Inc's Research & Development amounts to -11.9m USD.
What is Acer Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-7%
Over the last year, the Research & Development growth was -83%. The average annual Research & Development growth rates for Acer Therapeutics Inc have been 5% over the past three years , -6% over the past five years , and -7% over the past ten years .
